Replies to post #5113 on Health Discovery Corp (HDVY)

[investor15]

Quest Licenses Another Epigenomics Biomarker
February 25, 2009
By a GenomeWeb staff reporter
Type size:
-
+EmailPrinter-friendly versionRSS FeedNEW YORK (GenomeWeb News) — Quest Diagnostics has licensed a biomarker for prostate cancer from Epigenomics, which it plans to use to develop a molecular diagnostic test for diagnosing the disease, Epigenomics said today.

The agreement gives Quest the rights to use the GSTP1 DNA methylation biomarker in order to both develop and market the diagnostic test, which will be performed using patient tissue samples.

Quest licensed the rights to an Epigenomics biomarker for colorectal cancer in 2008 in order to develop a test to help detect that disease.

Financial terms of the agreement were not released.

The clinical lab giant has experience in developing DNA methylation diagnostic tests. It currently offers two such tests, one for Prader-Willi syndrome and one for Angelman syndrome, both of which are neurological epigenetic disorders that may be caused by faulty DNA methylation.

http://www.genomeweb.com/node/912354?emc=el&m=319663&l=1&v=277640021d

I'll drop off the kids and see what else I can find

[choo choo trader]

The Epigenomics Epi proColon test has sensitivity of 70% and specificity of 90%. HDC's developing blood test for colon cancer has sensitivity of 93% and specificity of 93%. It looks like HDC is building a better mouse trap.


From Epigenomics Clinical Data:

Clinical sensitivity and specificity. The performance of the biomarker mSEPT9 has been established in multiple independent studies with more than 3,000 individual plasma samples tested. The mSEPT9 assay consistently identified about 70% of cancers at a specificity of about 90% in training and testing studies 5. Depending on the population analyzed, performance data can vary.

choo